Using magnetocardiography to diagnose structural heart disease
Accurate Identification of Structural Heart Disease Using Magnetocardiography as an Innovative and Non-invasive Tool
This study is testing if a new heart imaging method called magnetocardiography can help diagnose heart problems better than traditional tests in people who might have structural heart disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2914 (estimated) |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06315998 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of magnetocardiography (MCG) in diagnosing structural heart disease by comparing its results with those obtained from transthoracic echocardiography and cardiac magnetic resonance imaging. Participants will include individuals suspected of having structural heart abnormalities who are scheduled for these standard imaging tests. The study will focus on various conditions such as cardiomyopathy, congenital heart defects, and valvular heart disease. By analyzing the parameters of MCG, the study seeks to improve diagnostic accuracy for these conditions.
Who should consider this trial
Good fit: Ideal candidates are individuals with suspected structural heart disease who are scheduled for echocardiography or cardiac magnetic resonance imaging.
Not a fit: Patients with arrhythmias or unstable clinical conditions that prevent them from completing the necessary examinations may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic capabilities for structural heart disease, leading to earlier and more accurate treatment.
How similar studies have performed: While the use of magnetocardiography is a novel approach, similar studies have shown promise in improving diagnostic methods for heart conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Those with suspected structural heart disease who are scheduled to undergo echocardiography or cardiac magnetic resonance. Structural heart disease includes cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, etc.), congenital heart disease (including ventricular septal defect, atrial septal defect, patent ductus arteriosus, Tetralogy of Fallot) syndrome, tricuspid valve malformation, etc.), valvular heart disease (aortic valve stenosis, mitral valve stenosis, etc.), ventricular remodeling caused by myocardial ischemia or cardiac structural changes. * Signed the consent form. Exclusion Criteria: * Those with atrial fibrillation, supraventricular tachycardia, atrioventricular block and other arrhythmias that have not returned to normal; * Those who are thought to be incapable of completing the relevant examinations by an attending physicians (or physicians with higher qualifications) due to unstable clinical conditions, metal implants, etc., or those who are unable to perform the examinations; * Those with obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply; * Those with malignant tumors; * Pregnant or lactating women.
Where this trial is running
Jinan, Shandong
- China, Shandong Qilu Hospital of Shandong University — Jinan, Shandong, China (Recruiting)
Study contacts
- Principal investigator: Yuguo Chen, Professor — Qliu Hospital of Shandong University
- Study coordinator: Jiaojiao Pang
- Email: jiaojiaopang@126.com
- Phone: 0086-0531-82165398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.